^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) +
    xentuzumab (BI-836845) (IGF-2 inhibitor, IGF1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.

    Published date:
    05/19/2021
    Excerpt:
    Xentuzumab plus abemaciclib and fulvestrant demonstrated encouraging disease control in pts with advanced HR+ BC with visceral and non-visceral disease.
    Secondary therapy:
    fulvestrant
    DOI:
    10.1200/JCO.2021.39.15_suppl.1057
    Trial ID:
    NCT03099174